Reply to DRS. Olanow and Rascol

Neurology

Volumn 74, Issue 14, 2010, Pages 1151-

  Ahlskog, J Eric ^a   Uitti, Ryan J ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE COURSE; HUMAN; NEUROPROTECTION; NOTE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 77951000307     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181d7d93b     Document Type: Note

References (3)

1. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-1371. (Pubitemid 19284193)
2. Parkinson Study Group. Effects of tocopherol and depre-nyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183. (Pubitemid 23021504)
3. Elm J, Goetz C, Ravina B, et al. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol 2005;57:197-203 (Pubitemid 40179857)